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(95%CI, 1.53 20.04; P = 0.009) for LSM 18.1 23 kPa; and
6.60 (95%CI, 1.83 23.84; P = 0.004) for LSM > 23 kPa.
Conclusion: Our data suggest that LSM could be a useful
predictor of HCC development in patients with CHB.
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Hepatocellular carcinoma (HCC) that develops in chronic
hepatitis B patients can express viral antigens from
chromosomally integrated hepatitis B virus (HBV) DNA.
Virus-speciﬁc T cells that could control HBV and eliminate
HCC expressing viral antigen are deleted or dysfunctional
in chronic patients. We have used T cell receptor (TCR)
gene transfer to reconstitute antiviral T cell immunity
in chronic HBV patients with the hope of developing a
cell-based therapy to target HBV-HCC and the underlying
chronic HBV infection. Using retroviral vectors we can
introduce HBV-speciﬁc TCRs into chronic HBV patient T
cells. We measure TCR expression using HLA-pentamers
and transduced T cell function by intracellular cytokine
staining, cytotoxicity and using a xenograft model of HCC
((gc)Rag2 / mice). The introduced TCRs are efﬁciently
expressed on the cell surface and result in polyfunctional
T cells (IFN-g, TNF-a, IL-2, Mip-b, MIP-a, IL-17, GM-CSF,
IL-8) that can lyse hepatocyte-like cell lines expressing
cognate HBV antigens. Adoptive transfer of TCR-redirected
T cells in the xenograft HCC model prevents formation of
the transplanted tumors and eliminates established tumors,
demonstrating their in vivo functionality. Furthermore, HBV-
speciﬁc TCR-redirected T cells can recognize Hep3B and
PLC-PRF5, HCC lines with natural HBV-DNA integration,
demonstrating they can respond to tumors expressing
viral antigen. Thus, TCR gene transfer can generate large
numbers of multifunctional HBV-speciﬁc T cells from chronic
HBV patient lymphocytes that are capable of recognizing
HBV infected hepatocytes and HCC tumor cells expressing
viral antigens from naturally integrated HBV genomes. These
genetically modiﬁed T cells could potentially be used to
reconstitute virus-speciﬁc T cell immunity for adoptive cell
therapy in chronic HBV and target tumors in HBV-related
HCC patients.
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Aims: To re-evaluate the carcinogenic signiﬁcance of
hepatitis B virus (HBV) integration in hepatocarcinogenesis.
Methods: Viral host genome junction sequences in both
tumor and paired corresponding non-tumor tissues from
HCC patients with chronic HBV infection were analyzed
using cassette ligation-mediated PCR (LM-PCR) and Alu-PCR
and direct sequencing. The integration sites were mapped
based on the acquired ﬂank sequence of human genome.
The potentially affected genes (interrupted directly by
integration or mapped within 100kb up- or downstream
of the viral-host junctions) were clustered based on their
function via gene ontology (GO) were performed to cluster
analysis. The somatic mutation and loss of heterogeneity
(LOH) of TP53 were screened by direct sequencing.
Array-based comparative genomic hybridization (aCGH) was
performed to detect the chromosomal aberrations in tumor
tissues.
Results: Collectively, a total of 232 different viral-
host sequences were identiﬁed in 68% (34/50) of tumor
and 70% (35/50) of non-tumor tissues. Among them,
chromosomal locations were determined in 87.52% (71/84)
of integrations in tumor tissues and 82.43% (122/148)
in non-tumor tissues, respectively. The viral-insert sites
were evenly distributed in all chromosomes including
X and Y. However, 35.71% (30/84) of integrants were
found within either exonic or intronic sequences of a
host gene in tumor tissues, and 35.13% (52/148) in non-
tumor tissues. Further GO annotation revealed that the
affected genes were enriched in transcription regulation
(9/31) and nucleus (12/31) with statistically signiﬁcant.
Such enrichment was not observed in non-tumor. Of 179
genes in tumor and 313 in non-tumor, which mapped
within 100 kb up- or downstream from or interrupted by
the HBV integration, GO annotation demonstrated that
genes involved in metabolism, transcription, and DNA-
binding were more enriched in tumor than in non-tumor.
In particular, 23.46% (42/179) genes were related with
transcription in tumor, but few genes were discovered in
non-tumor. When regarding to the HBV genome, 59.48%
(138/232) integrants contained X region sequences, 40.52%
(94/232) integrants contained pre C/C region sequences.
The break points of the integrants were mainly distributed
between the DR1 and DR2 of HBV. The percentages of 3′
deleted X gene caused by integration were 97.96% (48/49)
in tumor and 95.51% (85/89) in non-tumor tissues (p > 0.05).
Further analysis of these integrated 3′ truncated X gene
via immunohistochemistry assay detected few expression of
HBx in tumor. In addition, data from aCGH study indicated
that no direct correlation between chromosome instability
and HBV integration, while mutations or LOH of TP53 were
found in most tumor tissues with greater chromosome
instability.
Conclusions: HBV DNA integration could be observed in
both tumor and non-tumor tissues, with similar rates of
HBV C or X region integration. A similar frequency of
integrated X gene 3′ truncated deletion in tumor and
corresponding non-tumor tissues did not support a role
in hepatocarcinogenesis. Chromosomal instability (CIN) has
no prominent correlation with HBV integration. GO analysis
showed that genes located surrounding or interrupted by
the HBV integration in tumor tissues were clustered with
functions more relevance to transcription, nucleus and so
on, indicating that HBV integration affecting the expression
of the nearby genes is a previously unrevealed molecular
mechanism leading to cell malignant transformation.
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